Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
204 hedge funds and large institutions have $1.1B invested in Sage Therapeutics in 2024 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 70 increasing their positions, 61 reducing their positions, and 24 closing their positions.
57% more call options, than puts
Call options by funds: $5.76M | Put options by funds: $3.67M
17% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 24
15% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 61
2.38% more ownership
Funds ownership: 94.92% → 97.3% (+2.4%)
2% more funds holding
Funds holding: 200 → 204 (+4)
11% less capital invested
Capital invested by funds: $1.23B → $1.1B (-$138M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$22M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$14.8M |
| 3 |
State Street
Boston,
Massachusetts
|
+$13.3M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.96M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$9.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$30.2M |
| 2 |
CAC
Cowen and Company
New York
|
-$20.9M |
| 3 |
JP Morgan Chase
New York
|
-$11.9M |
| 4 |
Morgan Stanley
New York
|
-$11.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$6.29M |
SAGE Hedge Fund Activity: Q1 2024 in Review
204 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q1 2024, worth a combined $1.1B — down 11% from $1.23B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new SAGE positions and 24 closed out — a net gain of 4 holders — while 70 added to existing stakes and 61 trimmed.
The largest buyer was Bellevue Group, adding an estimated $22M. The largest seller was Wellington Management Group, cutting an estimated $30.2M.
- 204 institutional investors held Sage Therapeutics (SAGE) as of Q1 2024, up from 200 in Q4 2023.
- Funds reported $1.1B of Sage Therapeutics stock for Q1 2024, down 11% quarter-over-quarter.
- 28 funds opened new Sage Therapeutics positions in Q1 2024 and 24 closed out, a net change of +4 holders.
- The largest Sage Therapeutics buyer in Q1 2024 was Bellevue Group, an estimated $22M added.
- The largest Sage Therapeutics seller in Q1 2024 was Wellington Management Group, an estimated $30.2M sold.
Based on aggregated 13F filings for Q1 2024.